Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Class A common stock, par value $0.00001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
347
-
Total 13F shares, excl. options
-
79.8M
-
Shares change
-
+416K
-
Total reported value, excl. options
-
$11.9B
-
Value change
-
+$65M
-
Put/Call ratio
-
0.37
-
Number of buys
-
174
-
Number of sells
-
-146
-
Price
-
$148.96
Significant Holders of 10x Genomics, Inc. - Class A common stock, par value $0.00001 per share (TXG) as of Q4 2021
405 filings reported holding TXG - 10x Genomics, Inc. - Class A common stock, par value $0.00001 per share as of Q4 2021.
10x Genomics, Inc. - Class A common stock, par value $0.00001 per share (TXG) has 347 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 79.8M shares
of 114M outstanding shares and own 69.72% of the company stock.
Largest 10 shareholders include BlackRock Inc. (8.02M shares), VANGUARD GROUP INC (7.55M shares), FMR LLC (7.19M shares), BAILLIE GIFFORD & CO (6.88M shares), MORGAN STANLEY (4.86M shares), ARK Investment Management LLC (2.66M shares), 12 West Capital Management LP (2M shares), Foresite Capital Management II, LLC (1.75M shares), STATE STREET CORP (1.67M shares), and SANDS CAPITAL MANAGEMENT, LLC (1.66M shares).
This table shows the top 347 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.